Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105


Characterization of the evolution of immune phenotype during the development and progression of squamous cell carcinoma of the head and neck.

De Costa AM, Schuyler CA, Walker DD, Young MR.

Cancer Immunol Immunother. 2012 Jun;61(6):927-39. doi: 10.1007/s00262-011-1154-8. Epub 2011 Nov 25.


Treatment to sustain a Th17-type phenotype to prevent skewing toward Treg and to limit premalignant lesion progression to cancer.

Young MR, Levingston CA, Johnson SD.

Int J Cancer. 2016 May 15;138(10):2487-98. doi: 10.1002/ijc.29989. Epub 2016 Jan 28.


Administration of a vaccine composed of dendritic cells pulsed with premalignant oral lesion lysate to mice bearing carcinogen-induced premalignant oral lesions stimulates a protective immune response.

De Costa AM, Justis DN, Schuyler CA, Young MR.

Int Immunopharmacol. 2012 Jul;13(3):322-30. doi: 10.1016/j.intimp.2012.05.004. Epub 2012 May 16.


Premalignant Oral Lesion Cells Elicit Increased Cytokine Production and Activation of T-cells.

Johnson SD, Levingston C, Young MR.

Anticancer Res. 2016 Jul;36(7):3261-70.


Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies.

Levingston CA, Young MR.

Int J Cancer. 2017 Apr 1;140(7):1609-1619. doi: 10.1002/ijc.30543. Epub 2017 Jan 24.


Human Th17 cells can be induced through head and neck cancer and have a functional impact on HNSCC development.

Kesselring R, Thiel A, Pries R, Trenkle T, Wollenberg B.

Br J Cancer. 2010 Oct 12;103(8):1245-54. doi: 10.1038/sj.bjc.6605891. Epub 2010 Sep 28.


Blockade of adenosine A2A receptor enhances CD8+ T cells response and decreases regulatory T cells in head and neck squamous cell carcinoma.

Ma SR, Deng WW, Liu JF, Mao L, Yu GT, Bu LL, Kulkarni AB, Zhang WF, Sun ZJ.

Mol Cancer. 2017 Jun 7;16(1):99. doi: 10.1186/s12943-017-0665-0.


Oral premalignant lesions induce immune reactivity to both premalignant oral lesions and head and neck squamous cell carcinoma.

Young MR, Neville BW, Chi AC, Lathers DM, Boyd Gillespie M, Day TA.

Cancer Immunol Immunother. 2007 Jul;56(7):1077-86. Epub 2006 Nov 10.


Cytokines in head and neck cancer.

Pries R, Wollenberg B.

Cytokine Growth Factor Rev. 2006 Jun;17(3):141-6. Epub 2006 Mar 15. Review.


Immunomodulatory role of bitter melon extract in inhibition of head and neck squamous cell carcinoma growth.

Bhattacharya S, Muhammad N, Steele R, Peng G, Ray RB.

Oncotarget. 2016 May 31;7(22):33202-9. doi: 10.18632/oncotarget.8898.


Modulation of Th1 and Th2 cytokine profiles and their association with advanced head and neck squamous cell carcinoma.

Sparano A, Lathers DM, Achille N, Petruzzelli GJ, Young MR.

Otolaryngol Head Neck Surg. 2004 Nov;131(5):573-6.


Autocrine and paracrine loops between cancer cells and macrophages promote lymph node metastasis via CCR4/CCL22 in head and neck squamous cell carcinoma.

Tsujikawa T, Yaguchi T, Ohmura G, Ohta S, Kobayashi A, Kawamura N, Fujita T, Nakano H, Shimada T, Takahashi T, Nakao R, Yanagisawa A, Hisa Y, Kawakami Y.

Int J Cancer. 2013 Jun 15;132(12):2755-66. doi: 10.1002/ijc.27966. Epub 2012 Dec 17.


CD44 variant isoforms in head and neck squamous cell carcinoma progression.

Wang SJ, Wong G, de Heer AM, Xia W, Bourguignon LY.

Laryngoscope. 2009 Aug;119(8):1518-30. doi: 10.1002/lary.20506.


Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma.

Nakano H, Kishida T, Asada H, Shin-Ya M, Shinomiya T, Imanishi J, Shimada T, Nakai S, Takeuchi M, Hisa Y, Mazda O.

J Gene Med. 2006 Jan;8(1):90-9.


Immune response in cervical lymph nodes from patients with primary oral squamous cell carcinoma.

Gonçalves AS, Costa NL, Arantes DA, de Cássia Gonçalves Alencar R, Silva TA, Batista AC.

J Oral Pathol Med. 2013 Aug;42(7):535-40. doi: 10.1111/jop.12039. Epub 2012 Dec 26.


Supplemental Content

Support Center